Saudi Arabia enforces pharmaceutical tracking system through strict measures against non-compliant drug firms. The Saudi Food and Drug Authority (SFDA) announced fines totaling over SR4 million for violations in May. These penalties were issued to 19 pharmaceutical companies that failed to follow the country’s mandatory tracking rules.
The SFDA explained that 16 firms did not report medicine movement through the approved Drug Track and Trace System (RSD). This system helps track medications from production to delivery. By neglecting to report, these companies violated national supply chain regulations.
In addition, two companies failed to ensure product availability in the market. One firm also failed to inform the SFDA about an expected supply interruption. The rules require a six-month advance notice in such cases. This non-compliance directly threatens patient access to critical medicines.
Saudi Arabia enforces pharmaceutical tracking system to strengthen supply chain transparency. The SFDA continues to monitor companies to ensure medicine safety and availability. These efforts reflect the government’s commitment to health sector integrity.
Moreover, the RSD system plays a vital role in tracking drugs in real-time. It ensures accurate data on inventory and distribution. Authorities can quickly identify shortages, delays, or risks. As a result, they can act faster to protect public health.
The SFDA urges all pharmaceutical firms to comply fully with the RSD requirements. It warned that more penalties will follow for those who violate the rules. Ongoing monitoring will focus on both local and imported drug supply chains.
Saudi Arabia enforces pharmaceutical tracking system as part of its broader strategy to protect citizens and residents. These actions aim to ensure all medicines remain safe, traceable, and accessible across the Kingdom.
